Mode
Text Size
Log in / Sign up

White-light colonoscopy sensitivity for adenomas is 0.54 with lower sensitivity for smaller lesionsStandard colonoscopy may miss some small precancerous growths

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that WLC sensitivity is lower for smaller adenomas, potentially impacting cost-effectiveness calculations.

This meta-analysis evaluates the sensitivity of white-light colonoscopy (WLC) for adenoma detection in patients undergoing tandem colonoscopy. The study utilizes a Bayesian model to estimate WLC sensitivity and identify potential overstatements of performance when compared to enhanced colonoscopy techniques.

Key findings indicate an overall WLC sensitivity of 0.54 (95% credible interval 0.41, 0.63). Sensitivity varies significantly by adenoma size: 0.49 for 1-5 mm adenomas (95% credible interval 0.35, 0.60), 0.64 for 6-9 mm adenomas (95% credible interval 0.43, 0.78), and 0.84 for adenomas 10 mm or larger (95% credible interval 0.70, 0.93). The model-implied miss rate was 0.35 (95% credible interval 0.30, 0.40).

Several limitations are noted, including the fact that tandem colonoscopy data identify miss rates rather than direct WLC sensitivity. Estimates are dependent on external assumptions regarding the relative performance of enhanced colonoscopy versus WLC. Furthermore, WLC sensitivity estimates varied based on prior specifications, particularly for small and flat adenomas. These findings suggest that WLC sensitivity may be lower than previously assumed in cost-effectiveness analyses for colorectal cancer screening.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the actual performance of white-light colonoscopy (WLC) compared to enhanced techniques. It provides specific sensitivity data for different adenoma sizes, which may inform the clinical context of how AI-assisted colonoscopy modestly boosts diminutive polyp detection but not larger polyps.

When doctors perform a colonoscopy, they are looking for adenomas. These are small growths that can turn into colorectal cancer if left alone. Most screenings use a standard white-light colonoscopy (WLC). However, new analysis suggests that the effectiveness of this standard method might be lower than we previously thought, especially when it comes to finding smaller growths.

Researchers looked at how often these growths are missed. They found that the sensitivity of white-light colonoscopy for overall adenomas was about 0.54. This means the detection rate was lower than some previous models suggested. For very small growths between 1 and 5 millimeters, the sensitivity was even lower, at 0.49. Larger growths of 10 millimeters or more were caught more often, with a sensitivity of 0.84.

It is important to note that these findings rely on specific mathematical models and assumptions about how different types of colonoscopy compare. Because the data depends on these external assumptions, the results might vary. These findings are particularly relevant for experts calculating the costs and effectiveness of cancer screening programs.

What this means for you:
Standard white-light colonoscopies may have lower detection rates for small precancerous growths than previously thought.

Common questions

How well does a standard colonoscopy find small growths?

The study found that white-light colonoscopy (WLC) had a sensitivity of 0.49 for adenomas between 1 and 5 mm. Larger adenomas of 10 mm or more were detected more often, with a sensitivity of 0.84.

What is the overall detection rate for adenomas?

The overall sensitivity for adenomas using white-light colonoscopy was found to be 0.54. This means the method is less effective at catching all growths than some previous models assumed.

Are these results certain for every patient?

The findings are based on mathematical models and external assumptions about how different colonoscopy types compare. Because of these assumptions, the results may vary, especially for small or flat adenomas.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Background. Tandem colonoscopy meta-analyses estimate adenoma miss rates, which have been used as a proxy for colonoscopy sensitivity. Doing so overstates sensitivity because it ignores lesions missed by both exams. Methods. We introduce Bayesian and frequentist approaches to estimate white-light colonoscopy (WLC) sensitivity from tandem colonoscopy meta-analyses. Neither approach assumes that the second colonoscopy is perfect. We apply both approaches to reanalyze data from a recent tandem colonoscopy meta-analysis, overall and across ten subgroups. Sensitivity analyses assess how assumptions about the relative performance of enhanced colonoscopy versus WLC affect estimates. Results. Under our Baseline specification, overall WLC sensitivity estimated by the Bayesian model was 0.54 [0.41, 0.63] (posterior mean and 95% credible interval). Sensitivity rose with lesion size: 0.49 [0.35, 0.60] for 1-5 mm adenomas, 0.64 [0.43, 0.78] for 6-9 mm adenomas and 0.84 [0.70, 0.93] for lesions 10 mm or larger. The frequentist plausible range encompassed the Bayesian estimate. The model-implied miss rate (0.35 [0.30, 0.40]) matched the original meta-analysis estimate and was stable across prior specifications. Assuming enhanced colonoscopy was perfect overstated overall sensitivity by 0.12 [0.06, 0.20]. Limitations. Tandem colonoscopy data identify the miss rate but not WLC sensitivity, so estimates depend on an external assumption about the relative performance of enhanced colonoscopy versus WLC. As a result, WLC sensitivity estimates varied with the prior specification, especially for small and flat adenomas. Conclusions. WLC sensitivity may be meaningfully lower than previously assumed in CRC screening cost-effectiveness analyses. Modelers should use colonoscopy sensitivity estimates that do not assume a second colonoscopy exam is perfect.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.